Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Anastrozole"" wg kryterium: Temat


Tytuł :
Changes in serum estradiol levels with Estring in postmenopausal women with breast cancer treated with aromatase inhibitors.
Autorzy :
Streff A; Vanderbilt University, Nashville, TN, USA.
Chu-Pilli M; University of Arizona Cancer Center, 1515 N Campbell Ave, Tucson, AZ, USA.
Stopeck A; Department of Medicine, Hematology/Oncology, Stony Brook University, Stony Brook, NY, USA.
Chalasani P; University of Arizona Cancer Center, 1515 N Campbell Ave, Tucson, AZ, USA. .
Pokaż więcej
Źródło :
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2021 Jan; Vol. 29 (1), pp. 187-191. Date of Electronic Publication: 2020 Apr 23.
Typ publikacji :
Clinical Trial, Phase II; Journal Article
MeSH Terms :
Anastrozole/*therapeutic use
Aromatase Inhibitors/*therapeutic use
Breast Neoplasms/*drug therapy
Estradiol/*blood
Estrogen Receptor Modulators/*therapeutic use
Estrogens/*adverse effects
Administration, Intravaginal ; Anastrozole/adverse effects ; Estrogen Receptor Modulators/adverse effects ; Estrogens/administration & dosage ; Estrogens/therapeutic use ; Female ; Humans ; Middle Aged ; Postmenopause ; Prospective Studies ; Retrospective Studies ; Vaginal Diseases/chemically induced ; Vaginal Diseases/drug therapy
Czasopismo naukowe
Tytuł :
Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis.
Autorzy :
Huang X; Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Weng X; Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Lin S; Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Liu Y; Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Luo S; Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Wang H; Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Ming WK; Department of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, Guangdong, China .; Harvard Medical School, Harvard University, Boston, MA, United States.
Huang P; Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China .
Pokaż więcej
Źródło :
BMJ open [BMJ Open] 2020 Aug 30; Vol. 10 (8), pp. e036107. Date of Electronic Publication: 2020 Aug 30.
Typ publikacji :
Journal Article
MeSH Terms :
Anastrozole/*therapeutic use
Antineoplastic Agents, Hormonal/*therapeutic use
Breast Neoplasms/*drug therapy
Fulvestrant/*therapeutic use
Anastrozole/administration & dosage ; Anastrozole/economics ; Antineoplastic Agents, Hormonal/administration & dosage ; Antineoplastic Agents, Hormonal/economics ; Breast Neoplasms/economics ; Breast Neoplasms/pathology ; Cost-Benefit Analysis ; Drug Costs ; Drug Therapy, Combination/economics ; Drug Therapy, Combination/methods ; Female ; Fulvestrant/administration & dosage ; Fulvestrant/economics ; Health Care Costs ; Humans ; Markov Chains ; Quality-Adjusted Life Years
Czasopismo naukowe
Tytuł :
The Effect of Theracurmin on Cognitive Function in an Older Patient with Chemobrain.
Autorzy :
Erken N; Department of Geriatric Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
Dost Gunay FS; Department of Geriatric Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
Soysal P; Department of Geriatric Medicine, Bezmialem Vakif University, Faculty of Medicine, Istanbul, Turkey.
Isik AT; Department of Geriatric Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
Pokaż więcej
Źródło :
Clinical interventions in aging [Clin Interv Aging] 2020 May 19; Vol. 15, pp. 691-693. Date of Electronic Publication: 2020 May 19 (Print Publication: 2020).
Typ publikacji :
Case Reports
MeSH Terms :
Anastrozole*/administration & dosage
Anastrozole*/adverse effects
Cognition Disorders*/diagnosis
Cognition Disorders*/drug therapy
Cognition Disorders*/etiology
Radiotherapy*/adverse effects
Radiotherapy*/methods
Breast Neoplasms/*therapy
Cognition/*drug effects
Curcumin/*administration & dosage
Aged ; Antineoplastic Agents, Hormonal/administration & dosage ; Antineoplastic Agents, Hormonal/adverse effects ; Breast Neoplasms/pathology ; Female ; Geriatric Assessment/methods ; Humans ; Mastectomy, Segmental/methods ; Nootropic Agents/administration & dosage ; Treatment Outcome
Raport
Tytuł :
First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis.
Autorzy :
Liao W; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37, GuoXue Xiang, Chengdu, 610041, China.; West China Biomedical Big Data Center, Sichuan University, Chengdu, 610041, China.
Huang J; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37, GuoXue Xiang, Chengdu, 610041, China.; West China Biomedical Big Data Center, Sichuan University, Chengdu, 610041, China.
Wu Q; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37, GuoXue Xiang, Chengdu, 610041, China.; West China Biomedical Big Data Center, Sichuan University, Chengdu, 610041, China.
Wen F; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37, GuoXue Xiang, Chengdu, 610041, China.; West China Biomedical Big Data Center, Sichuan University, Chengdu, 610041, China.
Zhang N; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37, GuoXue Xiang, Chengdu, 610041, China.; West China Biomedical Big Data Center, Sichuan University, Chengdu, 610041, China.
Zhou K; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37, GuoXue Xiang, Chengdu, 610041, China.; West China Biomedical Big Data Center, Sichuan University, Chengdu, 610041, China.
Bai L; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37, GuoXue Xiang, Chengdu, 610041, China.; West China Biomedical Big Data Center, Sichuan University, Chengdu, 610041, China.
Li Q; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37, GuoXue Xiang, Chengdu, 610041, China. .; West China Biomedical Big Data Center, Sichuan University, Chengdu, 610041, China. .
Pokaż więcej
Źródło :
Breast cancer (Tokyo, Japan) [Breast Cancer] 2020 May; Vol. 27 (3), pp. 399-404. Date of Electronic Publication: 2019 Dec 18.
Typ publikacji :
Journal Article
MeSH Terms :
Cost-Benefit Analysis*
Postmenopause*
Anastrozole/*economics
Antineoplastic Agents, Hormonal/*economics
Breast Neoplasms/*economics
Fulvestrant/*economics
Anastrozole/therapeutic use ; Antineoplastic Agents, Hormonal/therapeutic use ; Breast Neoplasms/drug therapy ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Female ; Follow-Up Studies ; Fulvestrant/therapeutic use ; Humans ; Prognosis ; Receptor, ErbB-2/metabolism ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism
Czasopismo naukowe
Tytuł :
A novel view of the separate and simultaneous binding effects of docetaxel and anastrozole with calf thymus DNA: Experimental and in silico approaches.
Autorzy :
Dareini M; Department of Biology, Faculty of Sciences, Mashhad Branch, Islamic Azad University, Mashhad, Iran.
Amiri Tehranizadeh Z; Medicinal Chemistry Department, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: .
Marjani N; Department of Biology, Faculty of Sciences, Mashhad Branch, Islamic Azad University, Mashhad, Iran.
Taheri R; Department of Biology, Faculty of Sciences, Mashhad Branch, Islamic Azad University, Mashhad, Iran.
Aslani-Firoozabadi S; Department of Biology, Faculty of Sciences, Mashhad Branch, Islamic Azad University, Mashhad, Iran.
Talebi A; Department of Biology, Faculty of Sciences, Mashhad Branch, Islamic Azad University, Mashhad, Iran.
NayebZadeh Eidgahi N; Department of Biology, Faculty of Sciences, Mashhad Branch, Islamic Azad University, Mashhad, Iran.
Saberi MR; Medicinal Chemistry Department, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: .
Chamani J; Department of Biology, Faculty of Sciences, Mashhad Branch, Islamic Azad University, Mashhad, Iran. Electronic address: .
Pokaż więcej
Źródło :
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy [Spectrochim Acta A Mol Biomol Spectrosc] 2020 Mar 05; Vol. 228, pp. 117528. Date of Electronic Publication: 2019 Oct 30.
Typ publikacji :
Journal Article
MeSH Terms :
Computer Simulation*
Anastrozole/*metabolism
DNA/*metabolism
Docetaxel/*metabolism
Anastrozole/chemistry ; Binding, Competitive ; Calorimetry ; DNA/chemistry ; Docetaxel/chemistry ; Kinetics ; Models, Molecular ; Nucleic Acid Denaturation ; Osmolar Concentration ; Scattering, Radiation ; Spectrometry, Fluorescence ; Thermodynamics ; Viscosity
Czasopismo naukowe
Tytuł :
Solar photo-Fenton treatment of the anti-cancer drug anastrozole in different aqueous matrices at near-neutral pH: Transformation products identification, pathways proposal, and in silico (Q)SAR risk assessment.
Autorzy :
Sanabria P; Instituto de Química-UFRGS, Av. Bento Gonçalves 9500, CEP 91501-970 Porto Alegre, RS, Brazil.
Scunderlick D; Instituto de Química-UFRGS, Av. Bento Gonçalves 9500, CEP 91501-970 Porto Alegre, RS, Brazil.
Wilde ML; Instituto de Química-UFRGS, Av. Bento Gonçalves 9500, CEP 91501-970 Porto Alegre, RS, Brazil.
Lüdtke DS; Instituto de Química-UFRGS, Av. Bento Gonçalves 9500, CEP 91501-970 Porto Alegre, RS, Brazil.
Sirtori C; Instituto de Química-UFRGS, Av. Bento Gonçalves 9500, CEP 91501-970 Porto Alegre, RS, Brazil. Electronic address: .
Pokaż więcej
Źródło :
The Science of the total environment [Sci Total Environ] 2021 Feb 01; Vol. 754, pp. 142300. Date of Electronic Publication: 2020 Sep 11.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents*
Water Pollutants, Chemical*
Anastrozole ; Hydrogen Peroxide ; Hydrogen-Ion Concentration ; Risk Assessment
Czasopismo naukowe
Tytuł :
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
Autorzy :
Cuzick J; Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University London, London, UK. Electronic address: .
Sestak I; Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University London, London, UK.
Forbes JF; Australia New Zealand Breast Cancer Trials Group Newcastle, University of Newcastle, Calvary Mater Hospital, Waratah, NSW, Australia.
Dowsett M; Ralph Lauren Centre for Breast Cancer Research, Royal Marsden, London, UK.
Cawthorn S; Breast Care Centre, Southmead Hospital, Bristol, UK.
Mansel RE; University Department of Surgery, University of Wales College of Medicine, Cardiff, UK.
Loibl S; German Breast Group, Frankfurt, Germany.
Bonanni B; Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Evans DG; Prevent Breast Cancer Unit, Nightingale Breast Screening Centre, Manchester University NHS Foundation Trust, Manchester, UK.
Howell A; Prevent Breast Cancer Unit, Nightingale Breast Screening Centre, Manchester University NHS Foundation Trust, Manchester, UK.
Pokaż więcej
Corporate Authors :
IBIS-II investigators
Źródło :
Lancet (London, England) [Lancet] 2020 Jan 11; Vol. 395 (10218), pp. 117-122. Date of Electronic Publication: 2019 Dec 12.
Typ publikacji :
Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Anastrozole/*therapeutic use
Aromatase Inhibitors/*therapeutic use
Breast Neoplasms/*drug therapy
Breast Neoplasms/*prevention & control
Administration, Oral ; Adult ; Aged ; Anastrozole/adverse effects ; Breast Neoplasms/epidemiology ; Breast Neoplasms/mortality ; Carcinoma, Ductal, Breast/drug therapy ; Carcinoma, Ductal, Breast/pathology ; Carcinoma, Intraductal, Noninfiltrating/drug therapy ; Carcinoma, Intraductal, Noninfiltrating/pathology ; Female ; Follow-Up Studies ; Humans ; Incidence ; Middle Aged ; Placebos ; Treatment Outcome ; United Kingdom/epidemiology
Czasopismo naukowe
Tytuł :
Anastrozole-induced pulmonary cryptococcosis in a patient with early breast cancer: A case report.
Autorzy :
Wei M; Department of Respiratory Medicine, Shandong Chest Hospital Affiliated to Shandong University, Jinan.
Xu YR; Department of Respiratory Medicine, Shandong Chest Hospital Affiliated to Shandong University, Jinan.
Liu K; Department of Orthopedics, Shijiazhuang Third Hospital, Shijiazhuang.
Wen P; Department of Respiratory Medicine, Shandong Chest Hospital Affiliated to Shandong University, Jinan.; Department of Respiratory Medicine, Qilu Hospital of Shandong University, Jinan, China.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Jan; Vol. 99 (2), pp. e18688.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Anastrozole/*adverse effects
Breast Neoplasms/*drug therapy
Cryptococcosis/*etiology
Lung Diseases, Fungal/*etiology
Anastrozole/therapeutic use ; Female ; Humans ; Middle Aged
Czasopismo naukowe
Tytuł :
Impact of chemotherapy on symptoms and symptom clusters in postmenopausal women with breast cancer prior to aromatase inhibitor therapy.
Autorzy :
Li H; Department of Health and Community Systems, School of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania.
Sereika SM; Center for Research and Evaluation & Department of Health & Community Systems, School of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania.
Marsland AL; Department of Psychology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Conley YP; Department of Health Promotion and Development, School of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania.
Bender CM; Department of Health and Community Systems, School of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania.
Pokaż więcej
Źródło :
Journal of clinical nursing [J Clin Nurs] 2019 Dec; Vol. 28 (23-24), pp. 4560-4571. Date of Electronic Publication: 2019 Sep 15.
Typ publikacji :
Journal Article
MeSH Terms :
Anastrozole/*adverse effects
Antineoplastic Agents/*adverse effects
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Aromatase Inhibitors/*adverse effects
Breast Neoplasms/*drug therapy
Aged ; Anastrozole/administration & dosage ; Antineoplastic Agents/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Aromatase Inhibitors/administration & dosage ; Breast Neoplasms/complications ; Breast Neoplasms/physiopathology ; Case-Control Studies ; Female ; Hormone Replacement Therapy ; Humans ; Middle Aged ; Pain/drug therapy ; Postmenopause ; Prospective Studies ; Syndrome
Czasopismo naukowe
Tytuł :
A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer.
Autorzy :
Robertson JFR; Division of Breast Surgery, The University of Nottingham, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK. .
Jiang Z; Department of Breast Cancer, Affiliated Hospital of Academy of Military Medical Sciences, No. 8 Dongda Street, Fengtai District, Beijing, 100071, China.
Di Leo A; 'Sandro Pitigliani' Medical Oncology Department, Hospital of Prato, Azienda USL Toscana Centro, Piazza Dell'ospedale 2, 59100, Prato, Italy.
Ohno S; Breast Oncology Center, Cancer Institute Hospital, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Pritchard KI; Sunnybrook Odette Cancer Centre and the University of Toronto, 2075 Bayview Ave, Toronto, ON, M4N 3M5, Canada.
Ellis M; Lester and Sue Smith Breast Center, Baylor College of Medicine, 6620 S Main St #1350, Houston, TX, 77030, USA.
Bradbury I; Frontier Science, Grampian View, Kincraig, Kingussie, PH21 1NA, UK.
Campbell C; Frontier Science, Grampian View, Kincraig, Kingussie, PH21 1NA, UK.
Pokaż więcej
Źródło :
Breast cancer (Tokyo, Japan) [Breast Cancer] 2019 Nov; Vol. 26 (6), pp. 703-711. Date of Electronic Publication: 2019 May 11.
Typ publikacji :
Comparative Study; Journal Article; Meta-Analysis
MeSH Terms :
Complementary Therapies*
Anastrozole/*therapeutic use
Aromatase Inhibitors/*therapeutic use
Breast Neoplasms/*drug therapy
Estrogen Receptor Antagonists/*therapeutic use
Fulvestrant/*therapeutic use
Receptors, Estrogen/*metabolism
Adult ; Aged ; Aged, 80 and over ; Anastrozole/administration & dosage ; Aromatase Inhibitors/administration & dosage ; Estrogen Receptor Antagonists/administration & dosage ; Female ; Fulvestrant/administration & dosage ; Humans ; Middle Aged ; Postmenopause ; Randomized Controlled Trials as Topic ; Remission Induction ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study.
Autorzy :
van Hellemond IEG; Department of Medical Oncology, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands.
Smorenburg CH; Department of Internal Medicine, Medical Centre Alkmaar, Alkmaar, the Netherlands.
Peer PGM; Biostatistics, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, the Netherlands.
Swinkels ACP; Clinical research department, Netherlands Comprehensive Cancer Organisation IKNL, Utrecht, the Netherlands.
Seynaeve CM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
van der Sangen MJC; Department of Radiation Oncology, Catharina Hospital, Eindhoven, the Netherlands.
Kroep JR; Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands.
de Graaf H; Department of Medical Oncology, Medical Centre Leeuwarden, Leeuwarden, the Netherlands.
Honkoop AH; Department of Medical Oncology, Isala Clinics, Zwolle, the Netherlands.
Erdkamp FLG; Department of Medical Oncology, Zuyderland Medical Centre, Sittard, the Netherlands.
van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Centre, Sittard, the Netherlands.
de Boer M; Department of Medical Oncology, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands.
de Roos WK; Department of Surgery, Gelderse Vallei Hospital, Ede, the Netherlands.
Linn SC; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Imholz ALT; Department of Medical Oncology, Deventer Hospital, Deventer, the Netherlands.
Tjan-Heijnen VCG; Department of Medical Oncology, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands.
Pokaż więcej
Corporate Authors :
Dutch Breast Cancer Research Group (BOOG)
Źródło :
International journal of cancer [Int J Cancer] 2019 Sep 01; Vol. 145 (5), pp. 1325-1333. Date of Electronic Publication: 2019 Mar 04.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Anastrozole/*administration & dosage
Breast Neoplasms/*drug therapy
Osteoporosis, Postmenopausal/*diagnosis
Osteoporosis, Postmenopausal/*therapy
Anastrozole/adverse effects ; Antineoplastic Agents, Hormonal/administration & dosage ; Antineoplastic Agents, Hormonal/adverse effects ; Bone Density/drug effects ; Female ; Fractures, Bone ; Humans ; Middle Aged ; Prospective Studies ; Tamoxifen/administration & dosage ; Tamoxifen/adverse effects
Czasopismo naukowe
Tytuł :
Long-Term Survival and Complete Response to Anastrozole in Breast Cancer Patient With Cutaneous Metastases Only.
Autorzy :
Sedloev T; Department of Surgery, University Hospital 'Tzaritza Joanna - ISUL', Medical University of Sofia, Sofia, Bulgaria .
Vlahova A; Department of Pathology, Medical University of Sofia, Sofia, Bulgaria.
Usheva S; Department of Surgery, University Hospital 'Tzaritza Joanna - ISUL', Medical University of Sofia, Sofia, Bulgaria.
Vasileva-Slaveva M; Department of Surgery, University Hospital 'Alexandrovska', Medical University of Sofia, Sofia, Bulgaria.
Spiridonova T; Department of Surgery, University Hospital 'Tzaritza Joanna - ISUL', Medical University of Sofia, Sofia, Bulgaria.
Spirdonov J; Department of Medical Imaging, University Hospital 'Tzaritza Joanna - ISUL', Medical University of Sofia, Sofia, Bulgaria.
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2019 Aug; Vol. 39 (8), pp. 4393-4398.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Anastrozole/*administration & dosage
Breast Neoplasms/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Skin Neoplasms/*drug therapy
Aged, 80 and over ; Anastrozole/adverse effects ; Aromatase Inhibitors/administration & dosage ; Breast/drug effects ; Breast/pathology ; Breast Neoplasms/pathology ; Disease-Free Survival ; Female ; Humans ; Neoplasm Recurrence, Local/pathology ; Skin Neoplasms/pathology ; Skin Neoplasms/secondary
Czasopismo naukowe
Tytuł :
[Local Recurrence of Breast Cancer Eight Years after Mastectomy-A Case Report].
Autorzy :
Adachi K; Dept. of Surgery, The Nippon Dental University School of Life Dentistry.
Suzuki S
Hirano T
Sakurai K
Pokaż więcej
Źródło :
Gan to kagaku ryoho. Cancer & chemotherapy [Gan To Kagaku Ryoho] 2020 Dec; Vol. 47 (13), pp. 2195-2197.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Breast Neoplasms*/drug therapy
Breast Neoplasms*/surgery
Mastectomy*
Aged ; Anastrozole ; Female ; Humans ; Letrozole ; Neoplasm Recurrence, Local
Czasopismo naukowe
Tytuł :
Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation.
Autorzy :
Ward MC; Levine Cancer Institute, Atrium Health, Charlotte, North Carolina.
Vicini F; 21st Century Oncology, Farmington Hills, Michigan.
Chadha M; Ichan School of Medicine at Mt. Sinai, New York City, New York.
Pierce L; University of Michigan, Ann Arbor, Michigan.
Recht A; Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Hayman J; University of Michigan, Ann Arbor, Michigan.
Thaker NG; Arizona Oncology, Tucson, Arizona.
Khan A; Memorial Sloan Kettering Cancer Center, New York City, New York.
Keisch M; Cancer HealthCare Associates, Miami, Florida.
Shah C; Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: .
Pokaż więcej
Źródło :
International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2019 Oct 01; Vol. 105 (2), pp. 296-306. Date of Electronic Publication: 2019 Jun 15.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Markov Chains*
Anastrozole/*therapeutic use
Antineoplastic Agents, Hormonal/*therapeutic use
Aromatase Inhibitors/*therapeutic use
Breast Neoplasms/*drug therapy
Breast Neoplasms/*radiotherapy
Aged ; Aged, 80 and over ; Anastrozole/economics ; Antineoplastic Agents, Hormonal/economics ; Aromatase Inhibitors/economics ; Breast Neoplasms/chemistry ; Breast Neoplasms/prevention & control ; Clinical Trials as Topic ; Cost-Benefit Analysis ; Dose Fractionation, Radiation ; Female ; Humans ; Mastectomy, Segmental ; Meta-Analysis as Topic ; Neoplasm Recurrence, Local/prevention & control ; Probability ; Prospective Studies ; Quality-Adjusted Life Years ; Radiotherapy/economics ; Radiotherapy, Adjuvant ; Receptors, Estrogen ; Relative Biological Effectiveness ; Risk ; Salvage Therapy/methods
Czasopismo naukowe
Tytuł :
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
Autorzy :
Tang M; NHMRC Clinical Trials Centre, The University of Sydney, Levels 4-6 Medical Foundation Building, 92-94 Parramatta Rd, Camperdown, NSW 2050, Australia. Electronic address: .
O'Connell RL; NHMRC Clinical Trials Centre, The University of Sydney, Levels 4-6 Medical Foundation Building, 92-94 Parramatta Rd, Camperdown, NSW 2050, Australia.
Amant F; Department of Oncology, University of Leuven, Oude Markt 13, 3000 Leuven, Belgium; Centre for Gynaecologic Oncology, Netherlands Cancer Institute and Amsterdam Medical Centres, Plesmanlaan 121, 1066, CX, Amsterdam, Netherlands.
Beale P; Concord Repatriation General Hospital, Hospital Rd, Concord, NSW 2139, Australia.
McNally O; Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia; Royal Women's Hospital, 20 Flemington Rd, Parkville, VIC 3052, Australia; University of Melbourne, Parkville, VIC 3010, Australia.
Sjoquist KM; NHMRC Clinical Trials Centre, The University of Sydney, Levels 4-6 Medical Foundation Building, 92-94 Parramatta Rd, Camperdown, NSW 2050, Australia.
Grant P; University of Melbourne, Parkville, VIC 3010, Australia; Mercy Hospital for Women, 163 Studley Rd, Heidelberg, VIC 3084, Australia.
Davis A; The Canberra Hospital, Yamba Dr, Woden, ACT 2606, Australia; Australian National University, Canberra, ACT 0200, Australia.
Sykes P; University of Otago Christchurch, Christchurch Women's Hospital, 2 Riccarton Ave, Christchurch Central, Christchurch 8011, New Zealand.
Mileshkin L; Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia; Royal Women's Hospital, 20 Flemington Rd, Parkville, VIC 3052, Australia; University of Melbourne, Parkville, VIC 3010, Australia; Mercy Hospital for Women, 163 Studley Rd, Heidelberg, VIC 3084, Australia.
Moujaber T; The Westmead Institute for Medical Research, The University of Sydney, 176 Hawkesbury Rd, Westmead, NSW 2145, Australia.
Kennedy CJ; The Westmead Institute for Medical Research, The University of Sydney, 176 Hawkesbury Rd, Westmead, NSW 2145, Australia; Department of Gynaecological Oncology, Westmead Hospital, Hawkesbury Rd, Westmead, NSW 2145, Australia.
deFazio A; The Westmead Institute for Medical Research, The University of Sydney, 176 Hawkesbury Rd, Westmead, NSW 2145, Australia; Department of Gynaecological Oncology, Westmead Hospital, Hawkesbury Rd, Westmead, NSW 2145, Australia.
Tan K; NSW Health Pathology, The Institute for Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Darcy Rd, Westmead, NSW 2145, Australia.
Antill Y; Frankston Hospital, Hastings Rd, Frankston, VIC 3199, Australia.
Goh J; Royal Brisbane and Women's Hospital, Bowen Bridge Rd and Butterfield St, Herston, QLD 4029, Australia; University of Queensland, St Lucia, QLD 4072, Australia.
Bonaventura T; Calvary Mater Newcastle, Edith St and Platt St, Waratah, NSW 2298, Australia.
Scurry J; Pathology New South Wales, Hunter New England, Lookout Rd, New Lambton Heights, NSW 2305, Australia; Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW 2308, Australia.
Friedlander M; Prince of Wales Clinical School, UNSW Sydney, NSW 2052, Australia; Royal Hospital for Women, Barker St, Randwick, NSW 2031, Australia.
Pokaż więcej
Źródło :
Gynecologic oncology [Gynecol Oncol] 2019 Sep; Vol. 154 (3), pp. 531-538. Date of Electronic Publication: 2019 Jun 18.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Anastrozole/*therapeutic use
Carcinoma, Ovarian Epithelial/*drug therapy
Cystadenocarcinoma, Serous/*drug therapy
Ovarian Neoplasms/*drug therapy
Receptors, Estrogen/*metabolism
Adult ; Aged ; Anastrozole/adverse effects ; Antineoplastic Agents, Hormonal/adverse effects ; Antineoplastic Agents, Hormonal/therapeutic use ; Carcinoma, Ovarian Epithelial/metabolism ; Carcinoma, Ovarian Epithelial/pathology ; Cystadenocarcinoma, Serous/metabolism ; Cystadenocarcinoma, Serous/pathology ; Female ; Humans ; Middle Aged ; Neoplasm Grading ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/metabolism ; Neoplasm Recurrence, Local/pathology ; Ovarian Neoplasms/metabolism ; Ovarian Neoplasms/pathology ; Postmenopause ; Progression-Free Survival ; Prospective Studies ; Quality of Life ; Receptors, Progesterone/metabolism ; Young Adult
Czasopismo naukowe
Tytuł :
Aromatase inhibition in ovarian cancer: repeated signals of efficacy but tools for patient selection remain elusive.
Autorzy :
Gourley C; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Edinburgh, UK. .
Pokaż więcej
Źródło :
Journal of gynecologic oncology [J Gynecol Oncol] 2019 Sep; Vol. 30 (5), pp. e98.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Anastrozole*
Ovarian Neoplasms*
Aromatase ; Estrogens ; Female ; Humans ; Neoplasm Recurrence, Local ; Patient Selection ; Receptors, Progesterone
Opinia redakcyjna
Tytuł :
Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2.
Autorzy :
Dudenkov TM; Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Liu D; Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Cairns J; Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Devarajan S; Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Zhuang Y; Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Ingle JN; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Buzdar AU; Department of Breast Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
Robson ME; Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Kubo M; RIKEN Center for Integrative Medical Sciences, Yokohama City, Japan.
Batzler A; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
Barman P; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
Jenkins GD; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
Carlson EE; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
Goetz MP; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Northfelt DW; Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona, USA.
Moreno-Aspitia A; Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Jacksonville, Florida, USA.
Desta Z; Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Reid JM; Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Kalari KR; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
Wang L; Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Weinshilboum RM; Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2019 Jul; Vol. 106 (1), pp. 219-227. Date of Electronic Publication: 2019 Mar 18.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Alkaline Phosphatase/*genetics
Anastrozole/*pharmacokinetics
Aromatase Inhibitors/*pharmacokinetics
Epistasis, Genetic/*genetics
Anastrozole/blood ; Anastrozole/therapeutic use ; Aromatase Inhibitors/blood ; Aromatase Inhibitors/therapeutic use ; Breast Neoplasms/drug therapy ; Chromosomes, Human, Pair 16/genetics ; Chromosomes, Human, Pair 2/genetics ; Female ; GPI-Linked Proteins/genetics ; Genome-Wide Association Study ; Genotype ; Humans ; Polymorphism, Single Nucleotide ; Postmenopause ; Receptors, Estrogen/biosynthesis
Czasopismo naukowe
Tytuł :
Preparation and in vitro/in vivo evaluation of anastrozole reservoir-type intravaginal ring.
Autorzy :
Xia L; Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Qiu S; Institute of Basic Medical Sciences, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Liu Z; National Research Institute for Family Planning, Beijing, China.
Ning M; National Research Institute for Family Planning, Beijing, China.
Pokaż więcej
Źródło :
Biomedical chromatography : BMC [Biomed Chromatogr] 2019 Apr; Vol. 33 (4), pp. e4459. Date of Electronic Publication: 2019 Jan 21.
Typ publikacji :
Journal Article
MeSH Terms :
Contraceptive Devices, Female*
Anastrozole/*analysis
Anastrozole/*pharmacokinetics
Anastrozole/chemistry ; Animals ; Chromatography, High Pressure Liquid ; Dogs ; Female ; Linear Models ; Reproducibility of Results ; Sensitivity and Specificity ; Tandem Mass Spectrometry
Czasopismo naukowe
Tytuł :
Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Autorzy :
Kazi A; Department of Pharmacology, United States; Biology Department, Loyola University, Baltimore, MD, 21210, United States.
Goloubeva O; Division of Biostatistics, University of Maryland School of Medicine and University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, 21201, United States.
Schech A; Department of Pharmacology, United States.
Yu S; Department of Pharmacology, United States.
Sabnis GJ; Department of Pharmaceutical Sciences, West Coast University, Los Angeles, CA, 90004, United States; Department of Pharmacology, United States. Electronic address: .
Pokaż więcej
Źródło :
The Journal of steroid biochemistry and molecular biology [J Steroid Biochem Mol Biol] 2020 Sep; Vol. 202, pp. 105697. Date of Electronic Publication: 2020 May 24.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Aromatase Inhibitors/*therapeutic use
Breast Neoplasms/*drug therapy
Cinnamates/*therapeutic use
Indoles/*therapeutic use
Mammary Neoplasms, Experimental/*drug therapy
Selective Estrogen Receptor Modulators/*therapeutic use
Anastrozole/pharmacology ; Anastrozole/therapeutic use ; Animals ; Antineoplastic Agents, Hormonal/pharmacology ; Antineoplastic Agents, Hormonal/therapeutic use ; Aromatase/metabolism ; Aromatase Inhibitors/pharmacology ; Breast Neoplasms/metabolism ; Cell Line, Tumor ; Cinnamates/pharmacology ; Estrogen Receptor Antagonists/pharmacology ; Estrogen Receptor Antagonists/therapeutic use ; Estrogen Receptor alpha ; Female ; Fulvestrant/pharmacology ; Fulvestrant/therapeutic use ; Humans ; Indoles/pharmacology ; Mammary Neoplasms, Experimental/metabolism ; Mice, Nude ; Postmenopause ; Selective Estrogen Receptor Modulators/pharmacology
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies